{"id":27663,"date":"2024-04-19T21:28:08","date_gmt":"2024-04-19T15:58:08","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=27663"},"modified":"2024-04-19T21:28:09","modified_gmt":"2024-04-19T15:58:09","slug":"efgartigimod-ph20-adapt-sc-study","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-ph20-adapt-sc-study","title":{"rendered":"Unveiling the Promising Long-Term Potential of Subcutaneous Efgartigimod PH20 in Managing gMG"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li><em>Efgartigimod PH20 is a combination subcutaneous (SC) infusion that contains efgartigimod alfa and hyaluronidase which may be used to improve muscle weakness in adults with <\/em>generalized myasthenia gravis (gMG)<em> who are anti-AChR antibody positive.<\/em><\/li>\n\n\n\n<li><em>The interim results presented by Argenx highlighted notable efficacy and tolerability of SC efgartigimod PH20. With manageable adverse events and consistent clinical improvements, it underscores the treatment&#8217;s promising potential for gMG.<\/em><\/li>\n<\/ul>\n\n\n\n<p>In the realm of treating gMG, the quest for safer and more effective therapeutic options is a perpetual endeavor. Amidst this pursuit, the interim results of the ADAPT-SC+ study shed light on the long-term safety, tolerability, and efficacy of SC <strong>efgartigimod PH20<\/strong>.<\/p>\n\n\n\n<p>The <strong>ADAPT-SC+<\/strong> study (NCT04818671), building upon the findings of its predecessor, ADAPT-SC, and the ADAPT+ open-label extension (OLE) study, delved into the realm of SC administration of efgartigimod PH20. Participants received efgartigimod PH20 SC in cycles of four once-weekly injections, with subsequent cycles initiated at least 28 days apart based on clinical evaluation. The Myasthenia Gravis Activities of Daily Living (MG-ADL) score served as the benchmark for assessing clinical efficacy. The study identified predominantly mild to moderate adverse events (AEs), with the most frequent being injection site erythema (29.1%), COVID-19 (22.3%), and headache (20.1%). Notably, injection site reactions remained manageable, did not necessitate treatment cessation, and showed a decline in occurrence with successive cycles, dropping from 34.6% (n=62\/179) in Cycle 1 to 11.5% (n=14\/122) in Cycle 6. Analysis revealed significant enhancements from baseline throughout the treatment course, exemplified by <strong>notable improvements in the MG-ADL total score<\/strong> (\u22124.1 [0.27%]), Myasthenia Gravis Quality of Life 15-Item Questionnaire, Revised (MG-QoL15r) (\u22125.1 [0.44%]), and EuroQoL 5-Dimension, 5-Level (EQ-5D-5L) (13.8 [1.54%]) as early as Cycle 1. These improvements persisted consistently and reproducibly up to Cycle 9. Remarkably, the observed enhancements paralleled those documented with efgartigimod IV during the ADAPT\/ADAPT+ trials, suggesting robust and comparable therapeutic efficacy.<\/p>\n\n\n\n<p><strong>Conclusion:<\/strong> The interim analysis of the ADAPT-SC+ trial illuminates the considerable promise of subcutaneous efgartigimod PH20 as a well-tolerated and effective therapeutic avenue for gMG. With its favorable long-term safety profile and notable clinical advancements echoing those observed with efgartigimod IV, subcutaneous efgartigimod PH20 emerges as a beacon of optimism in the realm of gMG treatment. It offers patients a pathway to enhanced quality of life and symptom management. As research unfolds, the journey towards expanding the therapeutic arsenal for gMG enters a new phase, heralding brighter prospects for patients and caregivers alike.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the realm of treating gMG, the quest for safer and more effective therapeutic options is a perpetual endeavor. Amidst this pursuit, the interim results of the ADAPT-SC+ study shed light on the long-term safety, tolerability, and efficacy of SC efgartigimod PH20. The ADAPT-SC+ study (NCT04818671), building upon the findings of its predecessor, ADAPT-SC, and [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":27667,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[22059,22060,22061],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-27663","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-aan","tag-aan-2024","tag-aan-2024-conference","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Efgartigimod PH20 ADAPT-SC+ Study | AAN 2024<\/title>\n<meta name=\"description\" content=\"The interim results of the ADAPT-SC+ study shed light on the long-term safety, tolerability, and efficacy of SC efgartigimod PH20.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/efgartigimod-ph20-adapt-sc-study\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Efgartigimod PH20 ADAPT-SC+ Study | AAN 2024\" \/>\n<meta property=\"og:description\" content=\"The interim results of the ADAPT-SC+ study shed light on the long-term safety, tolerability, and efficacy of SC efgartigimod PH20.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/efgartigimod-ph20-adapt-sc-study\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-19T15:58:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-19T15:58:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/17170409\/efgartigimod-ph20-adapt-sc-study.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Efgartigimod PH20 ADAPT-SC+ Study | AAN 2024","description":"The interim results of the ADAPT-SC+ study shed light on the long-term safety, tolerability, and efficacy of SC efgartigimod PH20.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-ph20-adapt-sc-study","og_locale":"en_US","og_type":"article","og_title":"Efgartigimod PH20 ADAPT-SC+ Study | AAN 2024","og_description":"The interim results of the ADAPT-SC+ study shed light on the long-term safety, tolerability, and efficacy of SC efgartigimod PH20.","og_url":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-ph20-adapt-sc-study","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-04-19T15:58:08+00:00","article_modified_time":"2024-04-19T15:58:09+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/17170409\/efgartigimod-ph20-adapt-sc-study.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-ph20-adapt-sc-study","url":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-ph20-adapt-sc-study","name":"Efgartigimod PH20 ADAPT-SC+ Study | AAN 2024","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-ph20-adapt-sc-study#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-ph20-adapt-sc-study#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/17170409\/efgartigimod-ph20-adapt-sc-study.png","datePublished":"2024-04-19T15:58:08+00:00","dateModified":"2024-04-19T15:58:09+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The interim results of the ADAPT-SC+ study shed light on the long-term safety, tolerability, and efficacy of SC efgartigimod PH20.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/efgartigimod-ph20-adapt-sc-study"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-ph20-adapt-sc-study#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/17170409\/efgartigimod-ph20-adapt-sc-study.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/17170409\/efgartigimod-ph20-adapt-sc-study.png","width":466,"height":284,"caption":"efgartigimod-ph20-adapt-sc-study"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/17170409\/efgartigimod-ph20-adapt-sc-study-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AAN<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AAN 2024<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AAN 2024 Conference<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AAN<\/span>","<span class=\"advgb-post-tax-term\">AAN 2024<\/span>","<span class=\"advgb-post-tax-term\">AAN 2024 Conference<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Apr 19, 2024","modified":"Updated on Apr 19, 2024"},"absolute_dates_time":{"created":"Posted on Apr 19, 2024 9:28 pm","modified":"Updated on Apr 19, 2024 9:28 pm"},"featured_img_caption":"efgartigimod-ph20-adapt-sc-study","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=27663"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27663\/revisions"}],"predecessor-version":[{"id":27665,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27663\/revisions\/27665"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/27667"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=27663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=27663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=27663"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=27663"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=27663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}